$AGEN
Agenus Inc.
XNAS
Why is AGEN down today? It is at $7.42 (-4.63%), and our scanner flagged it 89 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment AGEN spikes, and full due diligence on AGEN — key stats, earnings, dilution and insider activity. Free.
Get free $AGEN alerts the moment volume spikes
Our scanner flagged $AGEN 89 times in the last 30 days. Create a free account to track $AGEN, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $7.42
- Change today
- -4.63%
- Previous close
- $7.78
- 52-week range
- $2.71 – $8.70
- Market cap
- $324M
- Institutional own.
- 29.52%
- Total held
- 32.9%
- Tradeable float
- 27.9M 67% of shares · after 3% insiders + 30% institutions
- Short interest
- 7.1M ▲ +18% vs prior · as of 2026-07-15
- Short % of float
- 25.3%
- Days to cover
- 1.0d
- Avg daily volume
- 1.5M
- Exchange
- XNAS
- 5m
- 1.4x
- 15m
- 1.4x
- 1h
- 1.3x
- 1D
- 0.7x
Get free AGEN + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $AGEN down today?
AGEN is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 7 unusual-volume and momentum alerts on AGEN today, peaking at 14.0x its normal volume. Fresh from the SEC: AGENUS INC: Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer. A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystAgenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon CancerReported Previously announced oversubscribed $85 million private placement, with up to $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN executionReported ROBBIN addresses approximately 38,000 newly diagnosed U.S. patients annually and an estimated annual U.S. sales opportunity of more than $7 billion; initiation and first patient dosing are expected in the first quarter of 2027Reported BOT+BAL access programs expanded across additional countries and treating institutions, contributing $6.4 million in second-quarter pre-commercial product revenue, from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
Insiders buying6 buys, 0 sells last 3 months (29/0 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Armen Garo H Officer | Acquired (grant/award) | +5K 0.01% of company | added 1.3% | 371K | $16K at $3.35 | Jul 10, 26 |
Harrison Thomas L Director | Acquired (grant/award) | +9K 0.02% of company | added 22% | 48K | $31K at $3.58 | Jul 1, 26 |
Armen Garo H Officer | Acquired (grant/award) | +5K 0.01% of company | added 1.5% | 366K | $16K at $3.03 | Jun 26, 26 |
Armen Garo H Officer | Acquired (grant/award) | +5K 0.01% of company | added 1.4% | 361K | $16K at $3.30 | Jun 12, 26 |
Armen Garo H Officer | Acquired (grant/award) | +5K 0.01% of company | added 1.3% | 356K | $16K at $3.50 | May 29, 26 |
Armen Garo H Officer | Acquired (grant/award) | +5K 0.01% of company | added 1.3% | 351K | $16K at $3.58 | May 15, 26 |
Armen Garo H Officer | Acquired (grant/award) | +4K 0.01% of company | added 1.2% | 347K | $16K at $3.84 | May 1, 26 |
Armen Garo H Officer | Acquired (grant/award) | +3K | added 1.0% | 343K | $16K at $4.79 | Apr 17, 26 |
Armen Garo H Officer | Acquired (grant/award) | +5K 0.01% of company | added 1.4% | 339K | $15K at $3.33 | Apr 3, 26 |
Harrison Thomas L Director | Acquired (grant/award) | +9K 0.02% of company | added 31% | 39K | $31K at $3.32 | Apr 1, 26 |
Armen Garo H Officer | Acquired (grant/award) | +4K | added 1.2% | 335K | $15K at $3.71 | Mar 20, 26 |
Armen Garo H Officer | Acquired (grant/award) | +5K 0.01% of company | added 1.5% | 331K | $15K at $2.96 | Mar 6, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfActive shelf on file — the company can issue new shares on demand (valid ~3 years). If $AGEN runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$AGEN Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$AGEN Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
AGEN stock FAQ
Why is $AGEN down today?
AGEN is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 7 unusual-volume and momentum alerts on AGEN today, peaking at 14.0x its normal volume. Fresh from the SEC: AGENUS INC: Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer. A material company disclosure like this is often the real catalyst behind a move of this size.
What is the AGEN stock price today?
AGEN last traded at $7.42, down 4.63% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live AGEN alerts?
The AGEN Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged AGEN 89 times in the last 30 days.
What exchange is AGEN on?
AGEN (Agenus Inc.) trades on XNAS, with a market cap of about $324M.
Is AGEN good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge AGEN for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.